Released Presentations
PLENARY SESSIONS

HEARING THE PATIENT'S VOICE IN HEALTH CARE DECISION MAKING IN ASIA

Hearing the Patient's Voice in Health Care Decision Making in Asia
Bong-Min Yang, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea
Dream and Hope
Tao Guan, Patient and Founder, the Hemophilia Home of China, Beijing, China
How to Improve Better Life for RA Patients Beyond Hurdles
Hsiao-Yi Lin, Executive Director & Chairman of Reimbursement Policy Response Committee, Taiwan Rheumatology Association, Chief Physician, Division of Allergy, Immunology & Rheumatology, Taipei Veterans General Hospital, and Associate Professor, School of Medicine, National Yang-Ming University, Taipei, Taiwan
Consumer/Patient Voice in Drug Reimbursement Decision Making
John Forman, Executive Director, New Zealand Organization for Rare Disorders, Thorndon, Wellington, New Zealand

 

ELECTRONIC HEALTH RECORDS FOR INFORMED HEALTH CARE IN ASIA-PACIFIC: LEARNING FROM EACH OTHER

Electronic Health Records for Informed Health Care in Asia-Pacific: Learning From Each Other
Jianfei (Jeff) Guo, Professor of Pharmacoeconomics & Pharmacoepidemiology, Division of Pharmacy Practice & Administrative Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
EHR in Japan
Naoto Kume, Associate Professor, EHR Research Unit, Department of Social Informatics, Graduate School of Informatics, Kyoto University, Kyoto Prefecture, Japan
Electronic Health Records for Informed Health Care: Australia’s Experience
Libby Roughead, Research Professor, Division of Health Sciences, School of Pharmacy and Medical Sciences, and Director, the Quality Use of Medicines and Pharmacy Research Centre, the Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia
Lessons from Sources in B.R.I.D.G.E. TO DATA® & the US
Judith K. Jones, Executive Director, DGI, LLC and Primary Editor, B.R.I.D.G.E. TO DATA ®, formerly Director, US FDA’s Division of Drug and Biological Experience (now Office of Safety & Epidemiology), Fairfax, VA, USA

 

CHINA HEALTH CARE REFORM: WHO GAINS AND WHO LOSES?

Overview of Health Care Reform in Asia and Beyond
Isao Kamae, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, University of Tokyo, Tokyo, Japan
Health Care Reform in Korea
Soonman Kwon, Professor of Health Economics and Policy in the Program of Health Care Management and Policy and Former Dean of Graduate School of Public Health, Seoul National University, Seoul, South Korea
U.S. Health Care Reform
Joel Hay, Professor of Pharmaceutical Economics & Policy, USC Schaeffer Center, University of Southern California, Calabasas, CA, USA
China Health Care Reform: Who Gains and Who Loses?
Bernhard Schwartländer, World Health Organization Representative in China, Beijing, China

 

ISSUE PANEL PRESENTATIONS

IP1 : HOW TO CONSTRUCT REIMBURSEMENT SUBMISSIONS IN THE ABSENCE OF HEAD-TO-HEAD CLINICAL DATA: ITC, MTC, OR CEA?

CEA in the Absence of Head-to-Head Clinical Data
Danny Liew, Professor, Medicine (RMH), The University of Melbourne, Melbourne, Australia
What to Do in Absence of Head to Head Clinical Trial Data
Stephen Goodall, Associate Professor, Center for Health Economics Research & Evaluation (CHERE), University of Technology in Sydney, Sydney, Australia

 

IP2 : DISINVESTMENT IN ASIA-PACIFIC: HOW CAN THIS BE IMPLEMENTED IN HTA AND WHAT CAN BE LEARNED FROM EUROPE?

Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?
Craig Brooks-Rooney, Head, Asia-Pacific, Costello Medical Singapore Pte Ltd., Singapore, Singapore
Iñaki Gutierrez-Ibarluzea, Knowledge Manager, Basque Office for Health Technology Assessment, Vitoria-Gasteiz, Spain
Isao Kamae, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, University of Tokyo, Tokyo, Japan
Seang Teak Tan, Chief Executive Officer, City International Hospital, Ho Chi Minh City, Vietnam

 

IP3 : MANAGING HIGH-COST, INNOVATIVE PHARMACEUTICALS IN ASIA: IS SOMETHING LOST WHEN TRANSLATING THEORY INTO PRACTICE?

The Pricing Challenges faced in Taiwan
Yen-Huei (Tony) Tarn, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan
The Potential for Using Managed Entry Agreements
Adrian Towse, Director, Office of Health Economics (OHE), London, UK
Adapting Innovative Health Care Technologies
Jianwei Xuan, Advisory Professor, Fudan University, School of Public Health, Shanghai, China

 

IP4 : ENVISIONING ONCOLOGY COVERAGE DECISION FRAMEWORK: HOW DO CURRENT AND FUTURE TRENDS IN ASIA-PACIFIC AFFECT THE ACCESSIBILITY?

Current Practice of Oncology Reimbursement in Taiwan
Chang-Fang Chiu, Vice Superintendent, Cancer Center, China Medical University Hospital, Taipei, Taiwan
Envisioning Oncology Coverage Decision Framework: How Do Current And Future Trends In Asia-Pacific Affect The Accessibility?
Jittrakul Leartsakulpanitch, Director, Market Access, Asia Pacific, Johnson & Johnson Asia Pacific, Bangkok, Thailand
Envisioning Oncology Coverage Decision Framework: How Do Current And Future Trends In Asia-Pacific Affect The Accessibility?
Chuen Seng Tan, Director, HEOR and Real World Evidence, IMS Asia Pacific, Singapore, Singapore

 

IP5 : THE PATIENT VOICE IN CHINA: WHAT IS THE WEIGHT OF PROS IN THE REIMBURSEMENT AND ACCESS DECISIONS OF PAYERS TODAY?

IP6 : UPDATING REIMBURSEMENT GUIDELINES IN ASIA PACIFIC: WHO’S DOING WHAT?

Updating Reimbursement Guidelines in the Asia Pacific: An Industry Perspective
Greg Cook, Associate Director, Bristol-Myers Squibb, Melbourne, Australia
Updating Drug Reimbursement Guidelines
Danny Liew, Professor, Medicine (RMH), The University of Melbourne, Melbourne, Australia
Guidelines for HTA: The Australian situation
Lloyd Sansom AO, Emeritus Professor, School of Pharmacy and Medical Sciences, University of South Adelaide, Adelaide, Australia

 

IP9 : DOES INVOLVING PATIENTS IN EVOLVING HTA PROCESSES IN ASIA-PACIFIC HELP OR HURT DECISION MAKING?

Does Involving Patients In Evolving HTA Processes In Asia-pacific Help or Hurt Decision Making?
Yen-Huei (Tony) Tarn, Executive Director, Center for Pharmaceutical Care Development,, Taiwan Pharmacist Association, Taipei, Taiwan
Does Involving Patients In Evolving HTA Processes In Asia-Pacific Help Or Hurt Decision Making?
Durhane Wong-Rieger, President & CEO, Institute for Optimizing Health Outcomes, Toronto, ON, Canada
HTA in Taiwan— Under The 2nd Generation NHI Act
Grace Hui-Min Wu, Researcher, Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, and Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan

 

IP10 : INFORMING TREATMENT PARADIGMS: WHAT ARE THE APPROACHES TO DATA COLLECTION IN ASIA-PACIFIC COUNTRIES?

Approaches to Data Collection: Practical Experience - Building Models from the Literature versus Deriving Models from Databases
Andrew J Palmer, Professor, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia

 

WORKSHOP PRESENTATIONS

W1 : HOW ROBUST ARE POOLED ESTIMATES FROM META-ANALYSES?

How Robust are Pooled Estimates from Meta-analyses?
Olivia Wu, Professor of Health Technology Assessment, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK
Neil S Hawkins, Reader in Health Technology Assessment, London School of Hygiene & Tropical Medicine, London, UK
Nathorn Chaiyakunapruk, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia

 

W2 : GOING LOCAL – STRATEGY, TECHNIQUES, AND EFFICIENCY IN ASIA-PAC ADAPTATION OF USA AND EU-BASED ECONOMIC MODELS

Going Local - Strategy, Techniques And Efficiency In Asia-Pac Adaptation Of Usa- And Eu-Based Economic Models
Sandeep Duttagupta, Principal, CBPartners, New York, NY, USA
Amy Lin, Assistant HEOR Manager, Bayer Taiwan, Taipei, Taiwan
Cyrus A. Chowdhury, Chief Executive Officer, CBPartners, New York, NY, USA

 

W5 : WHY, WHAT, AND HOW TO APPLY “BIG DATA” APPROACH IN HEOR AND EVIDENCE BASED RESEARCH

Why, What, And How To Apply “Big Data” Approach In Heor And Evidence Based Research
Boxiong Tang, Partner, Perspective, Collegeville, PA, USA
Jianwei Xuan, Advisory Professor, Fudan University, School of Public Health, Shanghai, China
Bruce Chang-Ming Wang, Director, Alliance Life Sciences, New York, NY, USA
Lou Garrison, Professor, University of Washington Department of Pharmacy, Seattle, WA, USA

 

W6 : DEVELOPMENT OF INDIVIDUAL SIMULATION MODELS FOR HTA SUBMISSION IN ASIA

Development of Individual Simulation Models For HTA Submission In Asia
Ying Zheng, Research Associate, Health Economics and Epidemiology, Evidera, Bethesda, MD, USA
Thitima Kongnakorn, Research Scientist, Health Economics and Epidemiology, Evidera, Bangkok, Thailand
Ben Chen, Market Access Manager, Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan

 

W7 : USING WEIGHTED CRITERIA FOR MAKING DECISIONS ON OFF-PATENT MEDICINES: CASE STUDIES FROM CHINA, THAILAND, AND VIETNAM

Using Weighted Criteria for Making Decisions on Off-Patent Medicines: Case Studies From China, Thailand, and Vietnam
Shanlian Hu, 2014-2016 Chair, ISPOR Asia Consortium Health Technology Assessment Agencies and Health Care Policymakers & Payers (HTA & Policymakers) Committee, Professor of Health Economics, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China
Surachat Ngorsuraches, 2012-2014 Chair, ISPOR Asia Consortium Executive Committee and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand
Jie Shen, Head of Market Access, Abbott, Basel, Switzerland
Diana Brixner, Professor & Chair, Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA

 

W8 : INCORPORATING THE PATIENT VOICE IN HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING: EXPERIENCES FROM THE UK AND TAIWAN

Incorporating the Patient Voice in Health Technology Assessment Decision-Making: Experiences From the UK and Taiwan
Olivia Wu, Professor of Health Technology Assessment, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK
Neil S Hawkins, Reader in Health Technology Assessment, London School of Hygiene and Tropical Medicine, London, UK
Yen-Huei (Tony) Tarn, Executive Director, Center for Pharmaceutical Care Development, Taiwan Pharmacist Association, Taipei, Taiwan

 

W9 : TIME TRADE-OFF PROCEDURES FOR MEASURING HEALTH-STATE PREFERENCES

Time Trade-Off Procedures For Measuring Health-State Preferences
Nan Luo, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
Kim Rand-Hendriksen, Psychologist, Faculty of Medicine, University of Oslo, Oslo, Norway
Mark Oppe, Research Scientist, The EuroQol Group Foundation, Rotterdam, The Netherlands
Koonal Shah, Senior Economist, Office of Health Economics, London, UK

 

W11 : EXPECTED VALUE OF PERFECT INFORMATION: ACTIVE LEARNING THROUGH USER-FRIENDLY COMPUTATIONS, DISPLAYS, AND ASIA-PACIFIC APPLICATION DISCUSSIONS

Expected Value Of Perfect Information: Active Learning Through User-Friendly Computations, Displays, And Asia Pacific Application Discussions
Jonathan D Campbell, Assistant Professor, School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
R. Brett McQueen, Post Doctoral Fellow, School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Jonathan H. Watanabe, Assistant Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA
Nathorn Chaiyakunapruk, Professor of Health Economics, Discipline of Pharmacy, Monash University Malaysia, Selangor, Malaysia

 

W12 : MAXIMIZING ACCESS OF INNOVATIVE DRUGS IN CHINA

Access Opportunities for Pharma in China
Yixi Chen, Health Economics & Outcomes Research Advisor, Medical, Pfizer Investment Co. Ltd., Beijing, China
Use of pharmacoeconomics in decision making and weakness of pharmacoeconomic studies in China
Hengjin Dong, Executive Director, Center for Health Policy Studies, Zhejiang University School of Medicine, School of Public Health, Hangzhou, China
Maximizing Access of Innovative Drugs in China
Xin (Cindy) Gao, Senior Director, Pharmerit International, Bethesda, MD, USA
Drug Policy in China
Kejun Liu, Professor & Deputy Director, Department of Pharmaceutical Policy, China National Health Development Research Center, Beijing, China

 

W13 : EVIDENCE SYNTHESIS AND DECISION-MAKING WHEN RANDOMISED EVIDENCE DOES NOT SUFFICE

Evidence Synthesis and Decision-making When Randomized Evidence Does Not Suffice
Kristian Thorlund, Director, Redwood Outcomes, Vancouver, BC, Canada
Edward J Mills, Associate Professor, Stanford University, Stanford, CA, USA
Ping Wu, Associate Scientist, Shanghai Jiaotong University, Shanghai, China

 

W16 : DYNAMIC NETWORK EVALUATIONS: STAYING UP-TO-DATE WITH DECISION MAKING

Dynamic Network Evaluations: Staying Up-to-Date with Decision Making
Kristian Thorlund, Director, Redwood Outcomes, Vancouver, BC, Canada
Ping Wu, Associate Scientist, Shanghai Jiaotong University, Shanghai, China
Edward J Mills, Associate Professor, Stanford University, Stanford, CA, USA

 

W17 : THE GERMAN EFFICIENCY FRONTIER APPROACH FOR ECONOMIC EVALUATION AND APPLICABILITY IN ASIA

W18 : IRRATIONAL EXUBERANCE: CAN HTA EVER INCENTIVIZE INNOVATION? CASE STUDIES FROM KOREA AND TAIWAN

Can HTA Ever Incentivize Innovation? Case Studies from Korea and Taiwan
Sandeep Duttagupta, Principal, CBPartners, New York, NY, USA
Cyrus A. Chowdhury, Chief Executive Officer, CBPartners, New York, NY, USA
Amy Lin, Assistant HEOR Manager, Bayer Taiwan, Taipei, Taiwan
Su-Kyoung Ko, Market Access Director, Health & Value, Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea

 

W19 : REAL WORLD DATA GENERATION USING HEALTH CARE DATABASES IN JAPAN

DPC based Situation Analysis of Chemotherapy in Japan
Shinya Matsuda, Professor, Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Fukuoka, Japan

 

ISPOR FORUMS

: VALUE IN HEALTH REGIONAL ISSUES (VIHRI): WRITING QUALITY MANUSCRIPTS FOR SUCCESS

Value in Health Regional Issues (ViHRI): Writing Quality Manuscripts for Success
Bong-Min Yang, Co-Editor-in-Chief, Value in Health Regional Issues (Asia) and Professor of Economics, School of Public Health and Executive Director, Institute of Health and Environment, Seoul National University, Seoul, South Korea
The CHEERS statement
Nathorn Chaiyakunapruk, Co-Editor, ViHRI (Asia) and Professor of Health Economics, School of Pharmacy, Monash University Malaysia, Kuala Lumpur, Malaysia
Value in Health Regional Issues (ViHRI): Writing Quality Manuscripts for Success
Jianfei (Jeff) Guo, Co-Editor, ViHRI (Asia) and Professor, University of Cincinnati Medical Center, School of Pharmacy, Cincinnati, OH, USA
Focusing on Asia
Kenneth K. C. Lee, Co-Editor, ViHRI (Asia) and Professor of Pharmacy & Head of School of Pharmacy, Monash University Malaysia, Kuala Lumpur, Malaysia

 

: HTA IN HEALTH CARE DEVELOPMENT ASSISTANCE PROGRAMS: POTENTIAL AND CHALLENGES IN ASIA

HTA in Health Care Development Assistance Programs: Potential & Challenges in Asia
Shanlian Hu, 2014-2016 Chair, ISPOR Asia Consortium Health Technology Assessment Agencies and Health Care Policymakers & Payers (HTA & Policymakers) Committee, Professor of Health Economics, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China
HTA in Development Assistance to Health: Potential and Challenge in China
Kun Zhao, Professor & Director, Centre of Health Policy Evaluation and Technology Assessment and China National Health Development Research Centre, National Health and Family Planning Commission, Beijing, China
HTA in Health Care Development Assistance Programs Potential & Challenges in Asia
Jitendar Sharma, Head-Division of Healthcare Technology, National Health Systems Resource Center, Ministry of Health & Family Welfare, New Delhi, India
HTA in Development Assistance for Health: Potential and Challenges From MDR-TB In the Mekong Delta
Joanne Yoong, Assistant Professor, National University of Singapore, Singapore, Singapore

 

: ASSURING QUALITY HEALTH CARE DELIVERY IN ASIA

Assuring Quality Health Care Delivery in Asia
Guk-Hee Suh, 2012-2014 Chair, ISPOR Asia Consortium Health Service Providers (Clinicians) Committee and Professor of Psychiatry, Hallym University College of Medicine, Hangang Sacred Heart Hospital, Seoul, South Korea
How to Improve Better Life for RA Patients Beyond Hurdles
Hsiao-Yi Lin, Chief Physician, Division of Allergy, Immunology & Rheumatology, Taipei Veterans General Hospital, Associate Professor, School of Medicine, National Yang-Ming University and Executive Director & Chairman of Reimbursement Policy Response Committee, Taiwan Rheumatology Association, Taipei, Taiwan

 

: EVOLVING HEALTH SYSTEMS IN ASIA: OPPORTUNITIES AND CHALLENGES FOR INDUSTRY

Opportunities and Challenges: Medical Devices and Diagnostics
Sang-Soo Lee, Director, Corporate Affairs, Medtronic Korea, Co., Ltd., Seoul, South Korea

 

: PHARMACOECONOMICS (PE) GUIDELINES IN ASIA

Pharmacoeconomics Guidelines in Malaysia: Development, Content and Applications
Syed Mohamed Aljunid, President, ISPOR Malaysia Chapter and Professor of Health Economics, & Head of the International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia
Proposed Pharmacoeconomics Research guidelines for India (PEG India 2013)
E. Vigneshwaran, Director, ISPOR India-Andhra Pradesh Chapter, Head of Department, Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Andhra Pradesh, India

 

EDUCATIONAL SYMPOSIA

HEPATITIS C VIRUS (HCV) DISEASE BURDEN IN ASIA (CHINA, JAPAN, SOUTH KOREA, AND TAIWAN)

Evaluation of Hepatitis C Disease Burden in China
Lai Wei, Professor, Hepatology Research Institute, People’s Hospital, Peking University, Beijing, China
The Burden of Illness for Patients with HCV in Japan
Isao Kamae, Professor, Hepatology Research Institute, People’s Hospital, Peking University, Beijing, China

 

THINKING BEYOND COST-EFFECTIVENESS ANALYSIS: ALTERNATIVE ANALYTIC FRAMEWORKS FOR INFORMING VALUE TO STAKEHOLDERS

How Will Optimisation Modelling Help Cost-Effectiveness Analysis in Assessing the Economic Value of New Products Like Vaccines?
Baudouin Standaert, Head of Global Health Economics, GlaxoSmithKline Vaccines, Warve, Belgium
The Fiscal Consequences Attributed to Changes in Morbidity and Mortality Linked to Investments in Healthcare
Mark Connolly, Managing Director, Global Market Access Solutions, Switzerland and United States and Guest Researcher, University of Groningen, Groningen, The Netherlands

 

PROSPECTIVELY COLLECTING CANCER DATA IN CHINA: A CASE STUDY IN GASTRIC CANCER

Prospectively Collecting Cancer Data in China: A Case Study in Advanced Gastric Cancer
Adèle R Weston, Executive Vice President/Senior Scientist, Optum Life Sciences, Asia Pacific, Sydney, Australia
Peiyu Wang, Professor, School of Public Health, Peking University Health Science Center, Beijing, China
Qun Zhao, Professor, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China

 

DIABETES IN ASIA: PERSPECTIVES ON INNOVATION OPPORTUNITIES FOR PATIENTS, PROVIDERS, AND PAYERS

Innovation Opportunities From the HTA Perspectives in Korea
Eui Kyung Lee, Professor, School of Pharmacy, Natural Science Campus, Sungkyunkwan University, Geong-Gi-Do, South Korea
Challenges and Innovation Opportunities for Diabetes Management in Taiwan
Mei-Shu Lai, Professor & Director, Institute of Preventitive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Diabetes in China - Challenges and Opportunities
Jiuhong Wu, Director, Department of Pharmacy, 306 hospital of PLA, Beijing, China

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 6th Asia-Pacific Conference, see: the ISPOR Scientific Presentations Database an electronic database of nearly 44,500 research papers presented at ISPOR International Conference, ISPOR European Conference, and ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 6th Asia-Pacific Conference – Beijing, China
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS
EDUCATIONAL FORUM
STUDENT SHOWCASE
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.